Summary and opinion by Wendy Anderson.
A Congressional panel has shown their disregard for the health of the U.S. public by completely rejecting three amendments set forward last week by Dana Rohrahbacher (R-CA) and Jared Polis (D-CO).
The first amendment would have conducted the task force, such as the Drug Enforcement Agency, The Office of National Drug Control Policy, and the Food and Drug Administration, to study the potential for cannabis to serve as an alternative to opioids as pain management.
The second amendment would’ve required a study by the National Institutes of Health and the Center of Disease Control on the medical application of cannabis and opioids. It would’ve also necessitated the federal comparison of opioid overdose deaths between states which have legalized cannabis and those that haven’t.
The third proposed amendment was sponsored by Reps. Scott Perry (R-PA) and Bob Dold (R-IL), as well as with Polis, would’ve excluded cannabis plants high in CBD and low in THC from the federal definition of marijuana. These are plants that are rich in Cannabidiol such as the Charlette’s Web used for children with the severe form of epilepsy Dravet Syndrome.
The committee ruled all three out of order, which means they could not even be offered a vote on the floor. Not even a chance.
However, when the bill was put to vote after the all of the amendments were taken out it was passed right through. Meaning they are all in the pharmaceutical pocket and out of the interest of science and health of the people they are supposed to represent. This is not a shining move for this U.S. House Rules Committee especially the ones bragging on social media.
Read the original article here.
Comments will be approved before showing up.
Baltimore Ravens offensive lineman Eugene Monroe won’t be on the next roster, and it may be for his advocacy for medical marijuana. Monroe’s January recovery from a shoulder injury inspired him to write about marijuana versus opioids, and donate $80,000 to medical marijuana researchers at both Johns Hopkins University and the University of Pennsylvania. His work, he tweeted, was all for his “brothers… the players that make up the team… our future health and wellness.”
Unfortunately, his offseason, offtopic efforts failed to impress the Ravens officials. In the days leading up to his release, attitudes from the organization led Monroe to wonder if his marijuana advocacy was to blame. Interestingly, his original questions were less about the drug, and more about overall NFL healthcare.
It is arguable that reviewing old drug testing policies is going to be a big trend in U.S. companies in the nearest future. If the weed is legal, and the job can be done safely under cannabis influence, why would an employer be concerned about marijuana consumption enough to spend money on drug testing?
Current situation is creating a whole lot of consequences, like people easily cheating on drug tests by adding water to their urine, or other people making money on ‘weed detox sets’ that claim to free your system of cannabis traces in just three days. More than 93% test negative, but employers continue testing. In most cases, we just avoid working for companies that drug test employees.